Remicade

Pfizer files US lawsuit against Johnson & Johnson over "anticompetitive" practices related to Remicade biosimilar
Pfizer files US lawsuit against Johnson & Johnson over "anticompetitive" practices related to Remicade biosimilar
First Word Pharma
Pfizer
JNJ
Janssen
Remicade
biosimilars
Inflectra
Flag link:
Remicade: A Case Study in How U.S. Pricing and Reimbursement Curb Adoption of Biosimilars
Remicade: A Case Study in How U.S. Pricing and Reimbursement Curb Adoption of Biosimilars
Drug Channels
drug pricing
reimbursement
Remicade
biosimilars
Janssen
Inflectra
Pfizer
Renflexis
Merck
Flag link:
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
Motley Fool
JNJ
Remicade
Stelara
drug pricing
Imbruvica
Xarelto
Darzalex
devices
consumer health
Flag link:
FDA Form 483 for Celltrion May Offer a Glimpse Into Limited Uptake for Remicade Biosimilar
FDA Form 483 for Celltrion May Offer a Glimpse Into Limited Uptake for Remicade Biosimilar
RAPS.org
FDA
Celltrion
biosimilars
Pfizer
Inflectra
Remicade
Flag link:
Remicade Is a Litmus Test for PBMs
Remicade Is a Litmus Test for PBMs
Bloomberg
Remicade
PBMs
biosimilars
CVS Health
Express Scripts
Flag link:
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
Fierce Pharma
patents
AbbVie
Humira
Pfizer
Lipitor
Norvasc
GSK
Advair
Sanofi
Lantus
JNJ
Remicade
AstraZeneca
Crestor
Nexium
Amgen
Neulasta
Novartis
Diovan
Flag link:
Merck undercuts Pfizer on Remicade biosimilar price
Merck undercuts Pfizer on Remicade biosimilar price
BioPharma Dive
Merck
Pfizer
Remicade
drug pricing
biosimilars
Renflexis
JNJ
Flag link:
Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta
Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta
Endpoints
Samsung Bioepis
Remicade
FDA
biosimilars
JNJ
GSK
Benlysta
lupus
Flag link:
How did Johnson & Johnson beat back Remicade's biosim? Call it the art of the deal
How did Johnson & Johnson beat back Remicade's biosim? Call it the art of the deal
Fierce Pharma
JNJ
Remicade
biosimilars
Pfizer
Inflectra
Flag link:
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Yahoo/Reuters
Novartis
rheumatoid arthritis
generics
Sandoz
Amgen
Enbrel
JNJ
Remicade
AbbVie
Humira
Flag link:
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
Motley Fool
prescription data
Sanofi
Lantus
Roche
Herceptin
Avastin
Celgene
Revlimid
JNJ
Merck
Remicade
Biogen
Rituxan
Amgen
Enbrel
Gilead Sciences
Harvoni
AbbVie
Humira
Flag link:
UK watchdog accuses Merck of restricting biosimilar competition
UK watchdog accuses Merck of restricting biosimilar competition
Drug Delivery Business News
Merck
biosimilars
competition
UK
Remicade
Flag link:
J&J fires off legal salvo to block Samsung's Remicade biosim launch
J&J fires off legal salvo to block Samsung's Remicade biosim launch
Fierce Pharma
JNJ
Samsung Bioepis
Remicade
biosimilar
Flag link:
J&J discloses DOJ investigations into marketing, advisory practices
J&J discloses DOJ investigations into marketing, advisory practices
BioPharma Dive
JNJ
DOJ
drug marketing
Remicade
Olysio
Simponi
Stelara
Flag link:
U.S. prosecutors zero in on J&J marketing, targeting top immunology, hep C meds
U.S. prosecutors zero in on J&J marketing, targeting top immunology, hep C meds
Fierce Pharma
JNJ
drug manufacturing
immunology
hepatitis C
Remicade
Simponi
Stelara
Olysio
Flag link:
Second biosimilar of Remicade approved in the US, but J&J not rattled
Second biosimilar of Remicade approved in the US, but J&J not rattled
BioPharma Dive
Remicade
JNJ
biosimilars
Renflexis
Merck
Samsung Bioepis
Flag link:
J&J's Remicade sees 'very little' biosim erosion, but payers are sticking it to Xarelto
J&J's Remicade sees 'very little' biosim erosion, but payers are sticking it to Xarelto
Fierce Pharma
JNJ
Remicade
biosimilars
payers
Xarelto
Inflectra
Flag link:
How Decline in Remicade Is Affecting Merck’s Immunology Revenues
How Decline in Remicade Is Affecting Merck’s Immunology Revenues
Market Realist
Merck
Remicade
Flag link:
The 19 Best-Selling Prescription Drugs of All-Time
The 19 Best-Selling Prescription Drugs of All-Time
Motley Fool
Lipitor
Humira
Seretide
Remicade
Plavix
Enbrel
Rituxan
Herceptin
Avastin
Nexium
Zyprexa
Flag link:
The 3 Most Important Numbers for Johnson & Johnson
The 3 Most Important Numbers for Johnson & Johnson
Motley Fool
JNJ
devices
Remicade
Flag link: